A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00088608

Enrollment

Registered

2004-08-02

Start date

2004-04-30

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cushing's Syndrome

Brief summary

The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.

Interventions

DRUGSOM230 s.c.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with pituitary Cushing's disease within the two months prior to study entry * Patients for whom written informed consent to participate in the study has been obtained * Female patients of child bearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use barrier contraception throughout the course of the study, and for one month after the study has ended

Exclusion criteria

* Female patients who are pregnant or lactating * Patients who have been previously treated with certain medications may be required to be without certain medications prior to entering the study * Poorly controlled diabetes mellitus as indicated by the presence of ketoacidosis or HgbA1C \> 10 * Patients who have congestive heart failure, unstable angina, cardiac arrhythmia or history of acute MI less than one year prior to the study entry or clinically significant impairment in cardiovascular function (e.g. blood pressure of 190/100mmHg or greater) * Patients with chronic liver disease * Patients with clotting disorders or abnormal blood counts * History of immuno-compromise, including a positive HIV test result * Patients with active gall bladder disease * Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to dosing * Patients with active malignant disease (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)

Design outcomes

Primary

Measure	Time frame
Urinary Free Cortisol after 15 days of treatment	—

Secondary

Measure	Time frame
ACTH	—
Clinical manifestations	—
Pharmacokinetics	—
Serum cortisol	—
Tolerability	—
Development of biomarkers	—
Safety	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026